Recommendation of the President – Piasky (crovalimab)

On 26 June 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 84/2025 on the appraisal of drug Piasky (crovalimab), under drug program B.96 “Treatment of patients with paroxysmal nocturnal hemoglobinuria (ICD-10 D59.5)”

Publication in Public Information Bulletin (BIP) >>